Engineered immune cells take on tough leukemia

NCT ID NCT03222674

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of cell therapy for people with relapsed or refractory acute myeloid leukemia (AML). The treatment uses a patient's own immune cells, engineered to recognize six different targets on leukemia cells. The study aims to see if this approach is safe and can reduce cancer burden.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multi-CAR T cells targeting Muc1, CLL1, CD33, CD38, CD56, and CD123
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early, small trial (10 people) focused on safety. The therapy may not work or could cause severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.